- Home
- ATLCP vs INM Comparison
ATLCP vs INM Comparison
Compare ATLCP & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ATLCP
Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Current Price
Company Overview
Basic Information| Metric | ATLCP | INM |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | Canada |
| Employees | 417 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 3.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ATLCP | INM |
|---|---|---|
| Price | $24.12 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 893.9K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,798,116.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $1.13 |
| 52 Week High | N/A | $8.27 |
Technical Indicators
Market Signals| Indicator | ATLCP | INM |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 39.58 |
| Support Level | $23.73 | $1.16 |
| Resistance Level | $24.20 | $1.48 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 74.58 | 30.58 |
Price Performance
Historical ComparisonAbout ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.